Lung cancer progression process not limited to late stages of disease

Share this article:

A tumor-associated protein with cell-transforming properties has been identified as an attractive molecular target for the development of new therapies to prevent early-stage lung adenocarcinomas from progressing.

In a mouse model, the Rac1b protein stimulated a change in epithelial cells of the lung. The change, known as epithelial-mesenchymal transition (EMT), triggered tumor development and now appears to be a key step in lung cancer progression during the earliest stages of cancer, according to lead investigator and Mayo Clinic (Jacksonville, Florida) cancer biologist Derek Radisky, PhD.

Whereas normal cells recognize when they are dividing too rapidly and turn on programs that block inappropriate cell division, “here we found that early-stage lung cancer cells switch on EMT in order to bypass these controls,” Radisky explained in a Mayo Clinic statement describing the study findings, which were published in Science Translational Medicine (2012;4[142]:142ra95).

EMT requires the ability of cells and tissues to morph from one type to another and develop in an orchestrated fashion. The process is a well-recognized transition in many types of late-stage solid tumors, which use EMT to change the tumor cells into a form that can migrate through the blood. This leads Radisky and colleagues to believe that the same early-stage use of EMT they discovered in lung cancer is likely occurring in other cancers as well. Inhibiting the function of the Rac1b protein, which is expressed abundantly in stage 1 and stage 2 lung adenocarcinomas, may represent a way to prevent progression of early-stage lung cancers.

“This study offers us great new clues for a new approach to treating lung and possibly other cancers as early as possible,” stated Radisky.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Survival equivalent with cetuximab or bevacizumab in metastatic colorectal cancer

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.

Some aggressive cancers may respond to anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.

Pain and itch may indicate skin cancer

Pain and itch may indicate skin cancer

Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study.